Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Launched by JONSSON COMPREHENSIVE CANCER CENTER · Oct 29, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of imaging called FAPi PET/CT scans to help doctors understand how cancer and normal tissues absorb a special tracer called 68Ga-FAPi-46. The goal is to see if these scans can provide valuable information about different types of cancer, including breast, colon, and lung cancers, before surgery to remove tumors. Participants may also have the option to undergo another type of imaging called PSMA PET/CT, which looks at a different tracer, and if they haven't had a specific PET scan in the past month, they may receive that as well.
To join the study, participants need to be 65 years or older and scheduled for surgery to remove their cancer. They must be able to give written consent and stay still for up to an hour during the imaging. However, pregnant or nursing individuals cannot participate, and those who have recently started new cancer treatments may also be excluded. This trial aims to learn more about how these imaging techniques can improve cancer care and provide insights into various cancers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients with the following cancer types:
- • Breast cancer
- • Colon cancer
- • Esophageal cancer
- • Gastric cancer
- • Head and Neck cancer
- • Lung cancer
- • Ovarian cancer
- • Pancreatic cancer
- • Renal cancer
- • Uterus cancer
- • Patients who are scheduled to undergo surgical resection of the primary tumor and/or metastasis
- • Patient can provide written informed consent
- • Patient is capable of complying with study procedures
- • Patient is able to remain still for duration of imaging procedure (up to one hour)
- Exclusion Criteria:
- • Patient is pregnant or nursing
- • Patients with any new cancer therapy between the baseline 18F-FDG PET/CT and the investigational FAPI PET/CT
- • Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data
About Jonsson Comprehensive Cancer Center
The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Los Angeles, California, United States
Patients applied
Trial Officials
Jeremie Calais, MD
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials